Could Proxy Advisers Sway Investors to Vote ‘No’ on BMS-Celgene Merger? - Pharma News -BoardProspects

Could Proxy Advisers Sway Investors to Vote ‘No’ on BMS-Celgene Merger?

Pharma News Mar 21 2019 BoardBlogs

After Bristol-Myers Squibb and activist investor Starboard Value released dueling presentations on the planned $74 billion merger with Celgene earlier this week, Wall Street analysts started speculating about what might actually cause the deal to go south...
Read Full Article

Bookmark or Share this article

Login to comment.
Related Articles
- Are You Ready for an Advisory Board? Twelve Questions to Help You Decide By: Susan Hammond also categorized in BoardBlogs
- Great Advice for Board Candidates (and Boards) By: Mark Rogers also categorized in BoardBlogs
- AstraZeneca Director Pushing to Tie Exec Pay to Big Growth Promises also published in Pharma News
- Hewlett-Packard Shakes Up Management, Raises Outlook also mentions Management
- Everyone Gets Rated By Leigh Tucker also categorized in BoardBlogs
- Who’s in charge here? By: Charles Whipple also categorized in BoardBlogs
- Six Reasons To Consider Establishing An Advisory Board By: Susan Hammond also categorized in BoardBlogs
- Nonprofit Governance: Why It Matters to Attend Board Meetings By Susan Hammond also categorized in BoardBlogs
- Actavis Chairman Joins Zoetis Board Under Deal With Activist Investor Ackman also published in Pharma News
- The 70:20:10 Rule of Board Learning by Debra Beck also categorized in BoardBlogs

Search:
Categories
1. BoardProspects Features:
  BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content
Topics Mentioned
- Management
- acquisition
- Investors
- Risk
- Wall Street
- ISS
- Credit Suisse
- AstraZeneca
- Starboard Value
- Bristol-Myers Squibb
- Pascal Soriot
- CEO
- Merger
- stake